Newly published study demonstrates clinical utility of daxor's blood volume (bva-100®) diagnostic in the assessment of postural tachycardia syndrome (pots)

New york, april 29, 2021 (globe newswire) -- daxor corporation (nyse mkt: dxr), the global leader in blood volume measurement technology, today announces new data demonstrating the clinical utility of the bva-100 blood test in postural tachycardia syndrome (pots) published in the journal of the american college of cardiology from the vanderbilt autonomic dysfunction center in nashville, tn.
DXR Ratings Summary
DXR Quant Ranking